Abstract
To assess the long-term safety and tolerability of XEN496 in pediatric subjects with KCNQ2
developmental and epileptic encephalopathy (KCNQ2-DEE) who had participated in the primary
study (XPF-009-301).
Stanley Manne Children's Research Institute
Louis A. Simpson and Kimberly K. Querrey Biomedical Research Center
303 East Superior Street
Chicago, IL 60611
